Sagimet Biosciences Inc.
SGMT · Nasdaq · United States
Share price · SGMT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SGMT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 24 Sep 2026-12.6%
Nothing announced by SGMT that day or the session before.
- 14 Aug 2026+13.7%
- 5 Aug 2026+8.1%
- 4 Aug 2026+11.7%
- 27 Apr 2026+38.6%
- 15 Apr 2026+9.6%
Nothing announced by SGMT that day or the session before.
- 8 Apr 2026+10.0%
Nothing announced by SGMT that day or the session before.
- 26 Mar 2026+10.6%
Nothing announced by SGMT that day or the session before.
- 24 Feb 2026+12.1%
Nothing announced by SGMT that day or the session before.
- 29 Jan 2026-8.5%
Nothing announced by SGMT that day or the session before.
Share of unusual movement by asset
For each asset, the share of SGMT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Fatty acid synthase (FASN) · FASNSmall molecule | MASH / NASHGlioblastoma Recurrent Glioblastoma |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
August 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (14)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $16M | $111M+ $125M short-term inv. | $19M-$12M operating cash flow | report ↗ |
View 13 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $12M | $166M+ $74M short-term inv. | $14M-$11M operating cash flow | report ↗ |
| 2026-Q1 | — | $7.0M | $37M+ $68M short-term inv. | $11M-$8.6M operating cash flow | report ↗ |
| 2025-Q3 | — | $9.7M | $33M+ $84M short-term inv. | $13M-$10M operating cash flow | report ↗ |
| 2025-Q2 | — | $7.3M | $42M+ $83M short-term inv. | $10M-$9.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $15M | $65M+ $80M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2024-Q3 | — | $13M | $77M+ $75M short-term inv. | $15M-$20M operating cash flow | report ↗ |
| 2024-Q2 | — | $6.3M | $75M+ $70M short-term inv. | $8.1M-$5.6M operating cash flow | report ↗ |
| 2024-Q1 | — | $5.3M | $177M+ $17M short-term inv. | $6.6M-$6.2M operating cash flow | report ↗ |
| 2023-Q3 | $2.0M | $5.0M | $102M+ $0 short-term inv. | $6.3M-$3.9M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.7M | $19M+ $0 short-term inv. | $6.8M-$5.7M operating cash flow | report ↗ |
| 2023-Q1 | — | $4.5M | $12M | $6.6M-$7.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $6.8M | $2.2M | $7.5M-$6.2M operating cash flow | report ↗ |
| 2022-Q2 | — | $6.4M | $4.5M | $7.1M$0 operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $39M | $35M+ $78M short-term inv. | $13M-$46M operating cash flow | report ↗ |
Sagimet Biosciences reported a full-year 2025 net loss of $51.04M, with revenue not disclosed. Research and development expense was $39.05M, up 1.6% YoY. Cash, cash equivalents and marketable securities totaled $113.1M as of December 31, 2025.
The company completed a Phase 1 pharmacokinetic trial of denifanstat combined with resmetirom and plans to initiate a Phase 2 proof-of-concept trial in F4 MASH patients in the second half of 2026. A first-in-human Phase 1 trial of the FASN inhibitor TVB-3567 is ongoing, with a Phase 2 acne trial anticipated in 2026. License partner Ascletis reported positive topline results from an open-label Phase 3 acne trial, and China's NMPA accepted an NDA for denifanstat for moderate to severe acne. Sagimet also secured a global, exclusive license to TAPI's resmetirom API forms for a potential fixed-dose combination.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $38M | $76M+ $75M short-term inv. | $11M-$42M operating cash flow | report ↗ |
| 2023-FY | $2.0M | $20M | $75M+ $20M short-term inv. | $7.0M-$24M operating cash flow | report ↗ |
| 2022-FY | — | $25M | $0.2M+ $32M short-term inv. | $7.6M-$24M operating cash flow | report ↗ |
| 2021-FY | — | — | $57M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 9 sales ($4.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-14 | Kemble George · director | Option exercise | 326,618 | $6.36 | $2.1M | Form 4 |
| 2026-08-14 | Kemble George · director | Option exercise | 24,369 | $6.36 | $155K | Form 4 |
| 2026-08-14 | Kemble George · director | Open-market sale | 350,987 | $10.23 | $3.6M | Form 4 |
| 2026-08-14 | Kemble George · director | Option exercise (derivative) | 326,618 | — | — | Form 4 |
| 2026-08-14 | Kemble George · director | Option exercise (derivative) | 24,369 | — | — | Form 4 |
| 2026-08-11 | Kemble George · director | Option exercise | 9,751 | $6.36 | $62K | Form 4 |
| 2026-08-11 | Kemble George · director | Option exercise | 10,455 | $6.36 | $66K | Form 4 |
| 2026-08-11 | Kemble George · director | Open-market sale | 20,206 | $9.95 | $201K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 87 reporting institutions held 13.4M shares ($68.6M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,098,919 | $5.7M |
| 2 | Woodline Partners LP | 1,000,943 | $5.2M |
| 3 | MARSHALL WACE, LLP | 966,253 | $5.0M |
| 4 | BAKER BROS. ADVISORS LP | 952,996 | $5.0M |
| 5 | Affinity Asset Advisors, LLC | 868,020 | $4.5M |
| 6 | MILLENNIUM MANAGEMENT LLC | 862,303 | $4.5M |
| 7 | BlackRock, Inc. | 799,943 | $4.2M |
| 8 | HHLR ADVISORS, LTD. | 724,800 | $3.8M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 625,469 | $3.3M |
| 10 | D. E. Shaw & Co., Inc. | 411,570 | $2.2M |
| 11 | Blue Owl Capital Holdings LP | 333,877 | $1.7M |
| 12 | RAYMOND JAMES FINANCIAL INC | 317,550 | $1.7M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 309,522 | $1.6M |
| 14 | Hudson Bay Capital Management LP | 303,223 | $1.6M |
| 15 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 299,641 | $1.6M |